4th Novel Conjugate Summit

Welcome to the 4th Novel Conjugate Summit!

The field of conjugatable drugs is advancing at a rapid pace, with major collaborations like Nurix and Pfizer for antibody-degrader conjugates and Bicycle and Novartis for radiopharmaceuticals, which paves the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs.

The 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in bioconjugates. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates, join us to delve into each of their value propositions and navigate crucial considerations like target selection, PK/PD profiles, and translation into the clinic.

Connect with 100+ experts from big pharma, cutting-edge biotechs and conjugation and manufacturing providers, all sharing crucial insights on striking success with new formats and payloads.

Now is the time to expand your conjugate design toolkit to pursue emerging cancer targets and stay ahead in the race to deliver safer, more targeted therapies beyond traditional ADCs Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025!

URLs:
Brochure: https://go.evvnt.com/2739582-0?pid=10018
Tickets: https://go.evvnt.com/2739582-1?pid=10018
Website: https://go.evvnt.com/2739582-2?pid=10018

Prices:
Drug Developer Conference + Workshop Day: USD 4197.00,
Drug Developer Conference Only: USD 2999.00,
Academic Conference + Workshop Day: USD 3597.00,
Academic Conference Only: USD 2599.00,
Service Provider Conference + Workshop Day: USD 5097.00,
Service Provider Conference Only: USD 3699.00

Speakers: Akihiko Yamamoto, Senior Director, Eisai, Andrew Buesking, Senior Director, Prelude Therapeutics​, Arnaud Tiberghien, Associate Director, Bicycle Therapeutics, Arne Scheu, CEO, Valink Therapeutics, Caitlyn Miller, Co-Founder and CEO, TwoStep Therapeutics, Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies Inc., Christopher Leamon, Chief Scientific Officer, Fusion Pharmaceuticals, David White, Senior Vice President and Head of Drug Discovery, ProteinQure, Dong Xu, Senior Vice President, Head of Biostatistics and Data Management, OBI Pharma Inc., Gwenn Hansen, Chief Scientific Officer, Nurix Therapeutics, Hadi Falahatpisheh, Vice President - Research and Development, ALX Oncology Inc., Hong Wan, President, Chief Executive Officer and Co-Founder, Tallac Therapeutics, J Cory Kalvass, Research Fellow, AbbVie, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences Inc., Jijun Dong, Chief Scientific Officer, Salubris Biotherapeutics Inc., Kevin Hamblett, Senior Director, ADC Biology, Pfizer, Leo Qian, Co-Founder and Vice President - Discovery Research, Entrada Therapeutics Inc., Marc-Andre Kasper, Vice President Chemistry and Early Discovery, Tubulis GmbH, Oliver Schon, VP, Research and Development, BiVictriX Therapeutics Ltd, Qinsi Zheng, Principal Scientist, Orum Therapeutics, Stanley Lewis, Founder and Chief Executive Officer, A28 Therapeutics, Thomas Natoli, Senior Director, Dyne Therapeutics, Vicky Appleman, Associate Director, Oncology Drug Discovery, Takeda Pharmaceutical Co. Ltd., Vijaya Pattabiraman, Co-Founder and Chief Technology Officer, Bright Peak Therapeutics, Vimal Patel, Vice President - Chemistry, Manufacturing and Controls, RadioPharm Theranostics